TRVI News and Press, Trevi Therapeutics Inc. From 03/22/22

Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) PR Newswire Webinar will be held on Wednesday, March 30, 2022 , from 8:00 a.m. to 9:00 a.m. EDT NEW HAVEN, Conn. , ...

Trevi Therapeutics, Inc. (TRVI) Q4 2021 Earnings Conference Call March 17, 2022, 04:30 PM ET Company Participants Jennifer Good - President and Chief Executive Officer William Forbes - Chief Development Officer Lisa Delfini - Chief Financial Officer Conference Call Participants Annabel Samimy...

Trevi Therapeutics press release (NASDAQ:TRVI): Q4 GAAP EPS of -$0.28 misses by $0.03. As of December 31, 2021, the Company had total cash and cash equivalents of $36.8 million. For further details see: Trevi Therapeutics GAAP EPS of -$0.28 misses by $0.03

Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update PR Newswire Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistically Signifi...

The following slide deck was published by Trevi Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Trevi Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough PR Newswire Previously Announced Statistically Significant Interim Analysis Established Proof of Concept (p-value less than 0.0001) Efficacy and Safety Data Expected on the Ful...

Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022 Conference Call and Webcast to be Held at 4:30 p.m. EDT PR Newswire NEW HAVEN, Conn. , March 9, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc...

The shares of Trevi Therapeutics (NASDAQ:TRVI) have added ~52% in the pre-market Thursday after the clinical-stage biopharmaceutical company announced positive interim results for its investigational therapy Haduvio from a Phase 2 trial involving patients with chronic cough. The CAN...

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis Interim analysis showed primary efficacy endpoint of cough reduction was highly statistica...

Trevi Therapeutics (TRVI +9.8%) completed enrollment in its phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for pruritus associated with prurigo nodularis (PN). PN is a chronic inflammatory skin disease where an extremely itchy rash appears on parts of the body. The company expects to ...